Showing 3911-3920 of 5910 results for "".
- Viridian Announces Positive Topline Results from Phase 3 Trial of Veligrotug for TEDhttps://modernod.com/news/viridian-announces-positive-topline-results-from-phase-3-trial-of-veligrotug-for-thyroid-eye-disease/2482434/Viridian Therapeutics announced positive topline data from its THRIVE phase 3 clinical trial of VRDN-001, now branded as veligrotug, in patients with active thyroid eye disease (TED). Veligrotug, an intravenously administered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, demo
- Ocuphire Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopiahttps://modernod.com/news/ocuphire-initiates-vega-3-phase-3-trial-evaluating-phentolamine-ophthalmic-solution-075-for-presbyopia/2482432/Ocuphire Pharma announced the first dosing of participants in its VEGA-3 phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia. Ocuphire’s phentolamine ophthalmic solution 0.75% is being developed as a potential alternative t
- Atsena Therapeutics Publishes 12-Month Safety and Efficacy Data from Phase 1/2 Trial of ATSN-101 in LCA1https://modernod.com/news/atsena-therapeutics-publishes-12-month-safety-and-efficacy-data-from-phase-12-trial-of-atsn-101-in-lca1/2482431/Atsena Therapeutics announced 12-month safety and efficacy results from its phase 1/2 clinical trial of ATSN-101, an investigational gene therapy for Leber congenital amaurosis (LCA1), a rare inherited retinal disease causing severe vision impairment or blindness from infancy. The findi
- Ciliatech to Present 36-Month Follow-Up Results on Intercil Uveal Spacer at Ophthalmology Futures European Forumhttps://modernod.com/news/ciliatech-to-present-36-month-follow-up-results-on-intercil-uveal-spacer-at-ophthalmology-futures-european-forum/2482427/Ciliatech has announced that it will reveal the combined 36-month follow-up results of its SAFARI I & II clinical trials at the Ophthalmology Futures European Forum on September 5. The company will share data on its Intercil Uveal Spacer, a Cilioscleral Interpositioning Device (CID) designed
- Alcon Announces New Cataract Surgery Outcomes Data, Hosts Educational Program at ESCRShttps://modernod.com/news/alcon-announces-new-cataract-surgery-outcomes-data-hosts-educational-program-at-escrs/2482426/Alcon is set to unveil new scientific data at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in Barcelona, from September 6-10, 2024. The company will showcase its surgical ophthalmic products and equipment, highlighting innovations designed to optimize
- Oculus Unveils Pentacam Cornea OCThttps://modernod.com/news/oculus-unveils-pentacam-cornea-oct-at-escrs-2024/2482425/Oculus is introducing the Pentacam Cornea OCT, a tool that combines Scheimpflug technology with the world’s first pericentric OCT scanning system, according to a company news release. The device provides cornea specialists with imaging capabilities, capturing both Scheimpflug
- BlueRock Receives FDA Clearance for IND Application of OpCT-001 for Primary Photoreceptor Diseaseshttps://modernod.com/news/bluerock-therapeutics-receives-fda-clearance-for-ind-application-of-opct-001-for-primary-photoreceptor-diseases/2482422/Bayer subsidiary BlueRock Therapeutics announced that the FDA has cleared its investigational new drug (IND) application for OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived therapy designed to treat primary photoreceptor diseases. The clearance allows BlueRock to in
- Haag-Streit Introduces METIS Ophthalmic Microscope Systemhttps://modernod.com/news/haag-streit-unveils-metis-ophthalmic-microscope-system/2482418/Haag-Streit has introduced the METIS ophthalmic microscope system, which is designed to provide optical performance, ergonomic design, and advanced features tailored for precision and efficiency. Superior Optical Experience The METIS microscope integrates Haag
- Former Regenxbio Execs Announce Launch of Gene Therapy Company Tern Therapeuticshttps://modernod.com/news/former-regenxbio-execs-announce-launch-of-gene-therapy-company-turn-therapeutics/2482414/Tern Therapeutics announced its official launch alongside the successful closing of a $15 million financing round. Simultaneously, Tern revealed a global licensing agreement with Regenxbio to acquire two gene therapy programs—RGX-381 and RGX-181—now designated as TTX-381 and
- Aura Biosciences to Present Phase 2 Data on Belzupacap Sarotalocan for Choroidal Melanoma at Retina Society Annual Meetinghttps://modernod.com/news/aura-biosciences-to-present-phase-2-data-on-belzupacap-sarotalocan-for-choroidal-melanoma-at-retina-society-annual-meeting/2482412/Aura Biosciences announced that final data from its phase 2 study on the suprachoroidal administration of belzupacap sarotalocan (bel-sar) for treating small choroidal melanoma and indeterminate lesions will be presented at the Retina Society Annual Meeting. The event will take place from Septemb